Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04410133 · ClinicalTrials.gov registry record · Phase 3
Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
A Phase 3 study, sponsored by Blue Earth Diagnostics.
- Completed
- Registry status
- Phase 3
- Development phase
- 151
- Enrollment target
NCT04410133 is a Phase 3 study that has completed, run by Blue Earth Diagnostics. The registered enrollment target is 151 participants.
The verdict
NCT04410133, a Phase 3 study, has completed, sponsored by Blue Earth Diagnostics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 151 participants
- Enrollment target
Study Summary
An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation therapy
Interventions
- DRUG 18F fluciclovine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2020-10-26 |
| Est. Completion | 2023-06-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04410133
The ClinicalTrials.gov registry entry for NCT04410133 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blue Earth Diagnostics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18F fluciclovine is the first listed.
NCT04410133 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04410133 about?
NCT04410133 is a clinical study titled "Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases". An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation therapy
What is the current status of trial NCT04410133?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 151 participants. The study started on 2020-10-26. Estimated completion is 2023-06-05.
What interventions are being tested in trial NCT04410133?
The interventions under investigation include: 18F fluciclovine (DRUG).
Who is sponsoring clinical trial NCT04410133?
This trial is sponsored by Blue Earth Diagnostics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.